The UK approach to COVID-19 vaccination: why was it so different?
The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2021-05-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/the-uk-approach-to-covid-19-vaccination:-why-was-it-so-different? |
| id |
doaj-a8e726172cb240049e06579e404002cd |
|---|---|
| record_format |
Article |
| spelling |
doaj-a8e726172cb240049e06579e404002cd2021-05-25T09:28:12ZengBioExcel Publishing LtdDrugs in Context1740-43982021-05-01101910.7573/dic.2021-4-5The UK approach to COVID-19 vaccination: why was it so different?Peter MB EnglishThe vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of the AstraZeneca and Pfizer-BioNTech vaccines. These decisions were controversial at the time but have contributed enormously to the effectiveness of the vaccination programme. This is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom.https://www.drugsincontext.com/the-uk-approach-to-covid-19-vaccination:-why-was-it-so-different?covid-19policyvaccination |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Peter MB English |
| spellingShingle |
Peter MB English The UK approach to COVID-19 vaccination: why was it so different? Drugs in Context covid-19 policy vaccination |
| author_facet |
Peter MB English |
| author_sort |
Peter MB English |
| title |
The UK approach to COVID-19 vaccination: why was it so different? |
| title_short |
The UK approach to COVID-19 vaccination: why was it so different? |
| title_full |
The UK approach to COVID-19 vaccination: why was it so different? |
| title_fullStr |
The UK approach to COVID-19 vaccination: why was it so different? |
| title_full_unstemmed |
The UK approach to COVID-19 vaccination: why was it so different? |
| title_sort |
uk approach to covid-19 vaccination: why was it so different? |
| publisher |
BioExcel Publishing Ltd |
| series |
Drugs in Context |
| issn |
1740-4398 |
| publishDate |
2021-05-01 |
| description |
The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of the AstraZeneca and Pfizer-BioNTech vaccines. These decisions were controversial at the time but have contributed enormously to the effectiveness of the vaccination programme. This is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom. |
| topic |
covid-19 policy vaccination |
| url |
https://www.drugsincontext.com/the-uk-approach-to-covid-19-vaccination:-why-was-it-so-different? |
| work_keys_str_mv |
AT petermbenglish theukapproachtocovid19vaccinationwhywasitsodifferent AT petermbenglish ukapproachtocovid19vaccinationwhywasitsodifferent |
| _version_ |
1721427784874590208 |